1. Introduction {#sec1}
===============

AP is a common disease whose severity varies widely from mild forms only affecting the pancreas (80% of the patients) to severe forms associated with multiple organ failure (20% of the patients). The reported incidence is approximately 30--40 per 100 000 population per year and 25% will develop severe or life threatening complications \[[@B1], [@B2]\]. The mechanisms responsible for the development of pancreatitis have not yet been fully elucidated. However, it has been clearly known that one of the important factors, activating pancreatic stellate cells during pancreatic injury, is proinflammatory cytokines known to be upregulated early in the course of acute pancreatic inflammation \[[@B3], [@B4]\]. Genetic factors, especially related to cytokines, may play important roles in susceptibility to pancreatic injury, as well as in the severity and evolution of the inflammatory process \[[@B5]\].

Tumour necrosis factor *α* (TNF*α*), thought to be the first cytokine released, is a principal mediator of immune responses \[[@B6]\]. The gene that codifies for TNF*α* is located within the major histocompatibility complex (MHC) class III region in the short arm of the human sixth chromosome \[[@B7]\]. Two biallelic polymorphisms in the promoter region of the TNF*α* gene may be relevant for the production of TNF \[[@B8]\]. The first one at the position −238 nucleotides relative to the transcriptional start site lies within a putative regulator sequence where a G to A substitution defines two variants (TNF*α* ^−238^ G and TNF*α* ^−238^ A). The second polymorphism at position −308 is also a point mutation, where the presence of G defines the common variant TNF*α* ^−308^ G and A defines the less common variant TNF*α* ^−308^ A \[[@B9]\]. Although some researches have showen that SNPs of TNF*α* are associated with inflammatory diseases in pancreas, identification of an association between the polymorphisms of TNF*α* and susceptibility to AP is less clear \[[@B10]--[@B13]\]. In the present study, our aim was to determine the association between TNF*α* promoter polymorphism (TNF*α* ^−308^; TNF*α* ^−238^) and AP susceptibility in patients with AP and controls nested within the Hospital of Istanbul University, Turkey. We hypothesized these polymorphisms could influence the risk of AP. This article can be significant for the approach to the possible relationship between key inflammatory gene polymorphisms and pancreatitis.

2. Material and Methods {#sec2}
=======================

2.1. Study Population {#sec2.1}
---------------------

Blood samples were collected from 103 patients with AP seen at the Emergency Service, the Hospital of Istanbul University, Turkey between March 2008 and March 2009. The criteria for diagnosis of AP were: a clinical history consistent with the disease, appropriate radiological evidence, and serum amylase level greater than 3 times the upper limit of normal. The progress of individuals with regard to development of complications was monitored during their disease episode. The disease severity was classified as mild or severe according to criteria defined by the Atlanta Consensus Conference \[[@B14]\]. Cases consisted of 68 patients with mild and 35 patients with severe AP. As a control group, 92 healthy ethnically matched subjects were obtained during the same period to examine association between TNF*α* genotypes and susceptibility to pancreatitis. The controls showed no evidence of pancreatitis or cancer. Ethical approval for the study was obtained from the Local Research Ethics Committee, Istanbul, Turkey. All participants provided written informed consent. We recorded the smoking status in addition to age, BMI, sex and family history. For smoking status, a person who had smoked at least once a day for \>1 year in his or her lifetime was regarded as a smoker.

2.2. Selection of Single Nucleotide Polymorphisms {#sec2.2}
-------------------------------------------------

The human TNF*α* gene situated on the short arm of chromosome 6 at p21.3 locus \[[@B7]\]. We collected data on TNF*α* polymorphisms from publicly available databases, such as dbSNP (<http://www.ncbi.nlm.nih.gov/>) and HapMap Phase II database (<http://hapmap.org/index.html.en>). The studied SNPs (TNF*α* ^−308^ (rs1800629) and TNF*α* ^−238^ (rs361525)) were chosen according to the following criteria: (a) minor allele frequency of 5% or greater in Caucasians, according to literature data, (b) previous epidemiologic findings indicating associations with pancreatitis and cancer susceptibility.

2.3. Genotyping {#sec2.3}
---------------

Genomic DNA was extracted from blood samples using a sodium perchlorate/chloroform extraction as described by Daly et al. \[[@B15]\]. Genotypes of TNF*α* polymorphisms were determined by PCR-RFLP methods. Genotyping was performed without knowledge of subjects\' patients or control status. The sequences of primers were designed by GenBank (accession numbers; NT007592; NM000594). For PCR amplification, genomic DNA (100 ng--1 *μ*g) was added to 25 *μ*L of PCR master-mix as described by Daly et al. \[[@B15]\]. The PCR products were digested with the various restriction enzymes. Digestion products were analysed by electrophoresis on 10% polyacrylamide gels with TBE buffer. Band patterns representing the various genotypes are summarized in below.

For TNF*α* ^−308^ G \> A (rs1800629), primers were 5′-ATC TGG AGG AAG CGG TAG TG-3′ and 5′-AAT AGG TTT TGA GGG CCA TG-3′. The following PCR protocol was used: 94°C for 3 minutes; 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds; 72°C for 5 minutes. The PCR product was directly digested with 2 U *NcoI* restriction enzyme at 37°C for overnight. Digestion with *Nco*I produced an uncut 222-bp fragment from the mutant allele (TNF*α* ^−308^ A), 130- and 20-bp fragments from the wild-type allele (TNF*α* ^−308^ G).

For TNF*α* ^−238^ G \> A (rs361525), primers were 5′-ATC TGG AGG AAG CGG TAG TG-3′ and 5′-AGA AGA CCC CCC TCG GAA CC-3′. The following PCR protocol was used: 94°C for 3 minutes; 35 cycles of 94°C for 30 seconds, 57°C for 30 seconds, 72°C for 30 seconds; 72°C for 5 minutes. The PCR product was directly digested with 2 U *Msp*I restriction enzyme at 37°C for overnight. Digestion with *Msp*I produced an uncut 150-bp fragment from the mutant allele (TNF*α* ^−238^ A), 130- and 20-bp fragments from the wild-type allele (TNF*α* ^−238^ G).

To assess reliability of genotyping, analysis repeated on 10% of the samples.

2.4. Statistical Analysis {#sec2.4}
-------------------------

*S*tatistical analysis was conducted by using the computer software *Statistical Package for Social Sciences-*SPSS for windows (version 13.0) (Chicago, IL). ORs and 95% CIs were estimated by conditional logistic regression analyses based on the comparison of genotypes between patients with AP and healthy controls, adjusting for the potential confounders, age, BMI, sex, smoking. Hardy-Weinberg equilibrium was tested to compare the observed and expected genotype frequencies among cases and controls, respectively. A two-sided *P*-value \<.05 was considered to be statistically significant. For analyses of genotype frequencies, the wild-type category (chosen either as the most common wild-type frequency or arbitrarily if both alleles showed similar frequencies) was the reference group.

3. Results {#sec3}
==========

There were no significant differences between the cases and controls for the mean age and sex distribution, and this suggested that the matching based on these two variables was adequate. The mean age (±SD) was 52.7 (±15.1) years for patients and 46.7 (±16.4) years for controls (*P* = .729). In this study, a significant association was observed for interaction between BMI and AP risk (OR = 3.07; 95% CI: 1.68−5.60; *P* = .0002) ([Table 1](#tab1){ref-type="table"}). As it can be seen in [Table 2](#tab2){ref-type="table"}, no association between TNF*α* genotypes and family history of pancreatitis or any cancer was detected in our study. Firstly, we tested the association between two TNF*α* SNPs (TNF*α* ^−308^, TNF*α* ^−238^) and AP risk in our study of 103 cases and 92 controls. TNF*α* ^−308^ A and TNF*α* ^−238^G, the highest allele frequencies observed in our study, were 0.616 and 0.870 in cases compared with 0.587 and 0.891 in controls, respectively. The observed genotype frequencies of all seven SNPs in cases and controls conformed to the Hardy-Weinberg equilibrium. We then analyzed the differences between cases and controls in the distribution of genotype. Genotype distribution of two SNPs (rs1800629; rs361525) in cases and controls did not significantly differ (*P* \> .05) and thus these polymorphisms were not associated with risk of pancreatic cancer ([Table 2](#tab2){ref-type="table"}). Similarly, there was no significant difference in the distribution of two TNF*α* gene polymorphisms studied between patients with mild or severe diseases. Finally, we investigated the associations between smoking status both AP risk and the two TNF*α* polymorphisms. Smoking was slightly associated with the risk of AP (OR = 1.70; 95% CI: 0.95−3.04; *P* = .075) while it was no observation any association between smoking and the studied polymorphisms (*P* = .1).

4. Discussion {#sec4}
=============

The link between inflammation and the development of cancer has been recognized by a number of researchers since Rudolf Virchow noted leukocytes in neoplastic tissue and suggested that there was a connection between cancer and inflammation in 1863 \[[@B16], [@B17]\]. Although many forms of pancreatitis have been linked to a higher risk for pancreatic cancer, the relationship between the two is ill-defined \[[@B18], [@B19]\]. The course of chronic pancreatitis is characterized by recurrent episodes of AP, which cause parenchymal injury and necrosis, with increasing amounts of fibrosis, chronic inflammation, and parenchymal cell loss with each successive episode \[[@B20], [@B21]\]. Patients with chronic pancreatitis have an increased risk of developing pancreatic cancer with a rate 15- to 16-fold greater than that of the general population \[[@B20]\]. It can be seen that AP is first step in this pathway progressed from inflammation to cancer in pancreas. However, inflammation alone usually does not lead to cancer. Several factors have been implicated for the recent rise in the frequency of AP, including age, alcohol consumption, smoking, gallstones, diet high in animal fat, and genetic disorders \[[@B21], [@B22]\]. On the contrary to the results obtained from some researches \[[@B23], [@B24]\]. No association between the risk of AP and family history was detected in this study ([Table 1](#tab1){ref-type="table"}). It is indicated that smoking status, duration and intensity were risk factors for AP by the researchers \[[@B25]--[@B27]\]. We found that there was a weak association between cigarette smoking and development of AP in the study population (OR = 1.59; 95% CI: 0.89−2.84; *P* = .075) ([Table 1](#tab1){ref-type="table"}). Further investigation with more samples would be better to determine strictly this association. As to BMI, a significant association was observed for interaction between BMI and AP risk (OR = 3.07; 95% CI: 1.68−5.60; *P* = .0002) similar to the results obtained from Lindkvist et al. \[[@B28]\] and Gumbs \[[@B29]\]. However, there was no specifically interaction between any studied polymorphisms and BMI. In two SNPs, the risk of AP was higher than \<2-fold from the point of view of BMI (no data shown). The main limitation of our study is the relative small study size, which may result in less precise estimation of gene-environment interaction in AP.

TNF*α* expression in the pancreas is increased by the onset of experimental pancreatitis, and antagonism of TNF*α* reduces the severity of local pancreatic inflammation. Levels of soluble TNF*α* receptors, indicators of TNF*α* activity, have been found to be increased in patients with severe disease, and TNF*α* blockade has been shown to reduce mortality and ameliorate markers of severe systemic disease in experimental AP \[[@B30]--[@B34]\]. TNF*α* polymorphisms have been associated with susceptibility and outcome of various infectious, inflammatory and neoplastic diseases \[[@B35]--[@B37]\]. As to AP, identification of an association between the polymorphisms of TNF*α* and susceptibility to AP is less clear, although several SNPs in TNF*α* have been reported previously in both many forms of pancreatitis and pancreatic cancer. A significant association between TNF*α* at position −308 and −238 has recently been described in patients with chronic pancreatitis and with pancreatic cancer \[[@B13], [@B14], [@B38], [@B39]\] while some researches have reported no association between TNF*α* polymorphism and susceptibility chronic pancreatitis or pancreatic cancer \[[@B40]--[@B42]\]. Beranek et al. \[[@B43]\] found that TNF*α* ^−238^ might be a relevant risk factor for disease manifestation in families with hereditary pancreatitis. On the contrary, there was no association between TNF*α* ^−238^ polymorphism and the risk of AP (OR = 0.86; 95% CI: 0.75−1.77; *P* = .175) in the study ([Table 2](#tab2){ref-type="table"}). Balog et al. \[[@B12]\] obtained that TNF*α* ^−308^ A alleles were associated with risk of AP. They noticed that genotype assessments may be important prognostic tools to predict disease severity and the course of AP. However, Zhang et al. \[[@B44]\] found no association between AP and TNF*α* ^−308^ in Chinese population with AP. But, they suggest that TNF*α* ^−308^ A allele is associated with a susceptibility to severe sepsis complicating of AP. TNF*α* ^−308^was genotyped in AP patients in UK population by Sargen et al. \[[@B45]\] and Powell et al. \[[@B46]\]. They found that TNF*α* ^−308^ plays no part in determination of disease severity or susceptibility to AP. Similarly, we found there was no association between TNF*α* ^−308^ polymorphism and the risk of AP (OR = 1.63; 95% CI: 1.13−4.01; *P* = .145) ([Table 2](#tab2){ref-type="table"}). We have also observed that the TNF*α* gene polymorphisms studied were not associated with disease severity in AP (no data shown).

In conclusion, we obtained the results on the contrary to our hypothesis. It is unlikely that the studied SNPs (TNF*α* ^−308^ and TNF*α* ^−238^) will regulate AP. In complex biologic disease processes such as AP, the effect of an SNP in inflammation process may be minimized through the interaction of other factors. Also, there are several potential reasons for failing to observe any association between TNF*α* gene polymorphisms studied and levels of disease severity. It is, perhaps, therefore not surprising that single gene polymorphisms do not correlate with outcome in patients with mild or severe AP. Therefore, additional studies on a larger group of patients will be required to confirm these findings. Besides, further studies on the level of expression of TNF*α* gene and on the other potential SNPs in neighbouring genes and in other inflammatory cytokines may likely provide additional insight into the role and implications of alterations in individual susceptibility to AP. We believe that any clarification of mechanisms linking inflammation and cancers will be beneficial to the development of efficacious prevention and therapies of inflammation-associated cancers.
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###### 

Distribution of select characteristics among AP patients and controls.

                   Cases (%) *n* = 103   Control (%) *n* = 92   OR (95% CI)        *P*-value
  ---------------- --------------------- ---------------------- ------------------ -----------
  Gender                                                                           
   Male            55 (53.4)             45 (48.9)              1.00 (reference)   .532
   Female          48 (46.6)             47 (51.1)              1.2 (0.68−2.10)    
  Age                                                                              
   ≤60             30 (29.1)             25 (27.2)              1.00 (reference)   .729
   \>60            72 (69.9)             67 (72.8)              0.90 (0.48−1.68)   
   Missing         1 (1.0)               *---*                                     
  Family history                                                                   
   No              80 (77.7)             82 (89.1)              1.00 (reference)   .150
   Yes             18 (17.5)             10 (10.9)              1.85 (0.80−4.24)   
   Missing         5 (4.9)                                                         
  BMI\*                                                                            
   ≤25             48 (46.6)             25 (27.2)              1.00 (reference)   .0002
   \>25            55 (53.4)             67 (72.8)              3.07 (1.68−5.60)   
  Smoking status                                                                   
   Non-smoking     57 (55.3)             63 (68.5)              1.00 (reference)   
   Smoking         46 (44.7)             30 (32.6)              1.70 (0.95−3.04)   .075

\*BMI; body mass index (kg/m^2^).

###### 

Genotype frequencies of TNF*α* among cases and controls and the association with AP risk. ORs with 95% CI and *P*-values were calculated for wild/wild genotype versus wild/mutant and mutant/mutant genotypes.

  TNF*α* polymorphisms            Genotype    Cases (%) *n* = 103   Controls (%) *n* = 92   OR (95% CI)\*     *P*-value
  ------------------------------- ----------- --------------------- ----------------------- ----------------- -----------
  TNF*α* ^−308^G \> A rs1800629   GG          15 (14.6)             21 (22.8)               GG versus any A   .145
  GA                              43 (41.8)   34 (37.0)             1.63 (1.13−4.01)                          
  AA                              45 (43.7)   37 (40.2)                                                       
                                                                                                              
  TNF*α* ^−238^G \> A rs361525    GG          90 (87.4)             73 (79.4)               GG versus any A   .175
  GA                              8 (7.8)     18 (19.6)             0.86 (0.75−1.77)                          
  AA                              5 (4.9)     1 (1.1)                                                         

\*OR: odds ratio; CI: 95% confidence interval; OR adjusted for age, sex, BMI, smoking status for logistic regression analysis.
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